美国痴呆症死亡率:地方,区域和时间评估
Lucas Casagrande Passoni Lopes1
1Universidade de São Paulo, Faculdade de Medicina de Bauru, Bauru SP, Brazil.
Dementia & neuropsychologia
|February 11, 2026
概括
在美洲的痴呆症死亡率在2000年至2019年间有显著的变化,岛屿美洲的死亡率最高. 国家趋势也存在差异,突出了针对痴呆症护理的有针对性的公共卫生干预措施的需要.
科学领域:
- 全球卫生流行病学
- 老年学是一门学科.
- 公共卫生政策 公共卫生政策
背景情况:
- 痴呆症是一个重大的全球健康挑战,不成比例地影响着人口.
- 来自美洲的有限和分散的数据阻碍了有效的区域规划和痴呆症护理政策制定.
研究的目的:
- 用本地和区域视角分析美洲痴呆症死亡率的时间趋势.
- 确定美洲大陆内痴呆症死亡率的地理和时间模式.
主要方法:
- 从2000年到2019年年龄调整后的痴呆症死亡率的生态时间序列分析.
- 数据来源于泛美卫生组织,与国家和国际数据集进行交叉验证.
- 加入点回归用于检测显著的年度百分比变化和确定死亡率趋势.
主要成果:
- 痴呆症死亡率在美洲岛屿地区最高,各国之间存在很大差异.
- 在美国,加拿大和几个中美洲和南美洲国家观察到较高的发病率.
- 不同的国家趋势包括在一些国家稳步下降,在其他国家持续或不稳定的增长.
结论:
- 美国痴呆症死亡率的显著时间趋势强调了公共卫生干预的关键领域.
- 这些发现为未来关于医疗保健公平性和痴呆症结果的研究提供了基础.
- 该研究强调,需要制定特定区域的策略来解决痴呆症死亡率的问题.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...


